Oncology Biosimilars Market Report 2026
Download Free Sample Buy Now
Oncology Biosimilars Market Global Report 2026 Market Report Infographic Image
Item added to cart!

Published : January 2026

Pages : 250

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Purchase This Report Download Sample PDF
Purchase This Report

Oncology Biosimilars Market Report 2026

Global Outlook – By Drug Type (Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF) ), By Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types ), By Distribution Type (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy ) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Oncology Biosimilars Market Overview

• Oncology Biosimilars market size has reached to $11.35 billion in 2025

• Expected to grow to $21.28 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%

• Growth Driver: Patent Expirations Drive New Oncology Biosimilars

• Market Trend: Increasing Focus On Investments To Support The Battle Of Cancer

• North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Oncology Biosimilars Market?

Oncology biosimilars refer to biologically similar drugs or medications that are physiologically comparable to biological cancer treatments. Infection risk is increased by decreased white blood cell counts, which can be treated as a side effect of cancer therapy.

The main drug types of oncology biosimilars are monoclonal antibodies, immunomodulators, hematopoietic agents, and granulocyte colony-stimulating factor (G-CSF). Immunomodulators are a class of drugs that primarily target pathways involved in the treatment of multiple myeloma and a few other cancers. The types of cancer treated include breast cancer, colorectal cancer, blood cancer, neutropenia cancer, and non-small cell lung cancer, and the various distribution channels involved are hospital pharmacies, retail pharmacies, and online pharmacies.

Oncology Biosimilars Market Global Report 2026 Market Report bar graph

What Is The Oncology Biosimilars Market Size and Share 2026?

The oncology biosimilars market size has grown rapidly in recent years. It will grow from $11.35 billion in 2025 to $12.83 billion in 2026 at a compound annual growth rate (CAGR) of 13.0%. The growth in the historic period can be attributed to high cost of reference biologics, limited availability of oncology biosimilars, increasing cancer prevalence globally, growing hospital and pharmacy infrastructure, early regulatory approvals for monoclonal antibody biosimilars.

What Is The Oncology Biosimilars Market Growth Forecast?

The oncology biosimilars market size is expected to see rapid growth in the next few years. It will grow to $21.28 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to launch of new biosimilar drugs including pembrolizumab and pegfilgrastim, expansion of online pharmacy distribution channels, rising adoption of immunomodulators and hematopoietic agents, increasing government initiatives to improve cancer care access, growing focus on personalized oncology treatment. Major trends in the forecast period include rising adoption of rituximab, trastuzumab, and bevacizumab biosimilars, increasing use of immunomodulators and hematopoietic agents in cancer therapy, growth in g-csf biosimilars for neutropenia management, expansion of hospital and retail pharmacy channels for oncology biosimilars, focus on cost-effective and accessible cancer treatment options.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

Global Oncology Biosimilars Market Segmentation

1) By Drug Type: Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)

2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types

3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Monoclonal Antibody: Rituximab Biosimilars, Trastuzumab Biosimilars, Bevacizumab Biosimilars, Pembrolizumab Biosimilars

2) By Immunomodulators: Thalidomide Biosimilars, Lenalidomide Biosimilars, Pomalidomide Biosimilars

3) By Hematopoietic Agents: Epoetin Biosimilars, Darbepoetin Biosimilars

4) By Granulocyte Colony-Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

What Is The Driver Of The Oncology Biosimilars Market?

The expiration of the patent of biologics used for the treatment of cancer is driving the production of new oncology biosimilars. Biologics can be patented for a limited period and the expiration of patents for biologics allows the development of new biosimilars. Biologics are targeted drugs synthesized from living organisms that induce the immune system to attack cancer cells. Biosimilars are similar to biologics but are not identical and offer the same effectiveness as biologics at a reduced cost. For instance, in February 2024, according to the DrugTimes is a Chinese-based company focused on the pharmaceutical and biotech industry, by 2037, more than 25 products will lose patent protection, potentially resulting in a combined revenue decline exceeding $236.4 billion, based on 2024 sales figures. The increased number of patent expiry is expected to boost the demand for the production of new oncology biosimilars, thus, driving the market growth for the oncology biosimilars industry.

Key Players In The Global Oncology Biosimilars Market

Major companies operating in the oncology biosimilars market are Biocon Biologics Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen Inc., F. Hoffmann-La Roche, Sanofi SA, Mylan, Samsung Bioepis, Biogen International GmbH, Merck & Co. Inc., Coherus Biosciences, Eli Lilly and Company, Novartis AG, Viatris Inc., Accord Healthcare Ltd., Zydus Cadila Health Care Limited, Hetero Drugs Limited, Mundipharma International Limited, Mabion SA, Polpharma Biologics, Alvotech, Innovent Biologics, Gan & Lee Pharmaceuticals, Henlius Biotech

Global Oncology Biosimilars Market Trends and Insights

Major companies operating in the oncology biosimilars market are focusing on developing innovative cancer therapies such as targeted biologics and monoclonal antibodies to enhance treatment efficacy, patient outcomes, and overall accessibility in oncology care. Monoclonal antibodies (mAbs) are lab-engineered proteins designed to recognize and bind specific cancer cell antigens, enabling precise targeting and immune-mediated destruction. For instance, in March 2023, Pfizer, a US-based pharmaceutical company, merged with Seagen and invested $43 billion to strengthen its oncology portfolio. This strategic move enhances Pfizer’s presence in cancer therapeutics and accelerates the development of advanced treatments against cancer, a leading cause of death worldwide. The investment also underscores the growing trend of significant capital allocation toward innovative oncology biosimilars to address unmet medical needs and expand global access to cancer care.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Oncology Biosimilars Market?

In October 2024, Teva Pharmaceuticals Inc., an Israel-based pharmaceutical company, formed a partnership with mAbxience, to advance next-generation oncology biosimilar solutions. The collaboration aims to improve access to, and broaden the development of, high-quality oncology biosimilars, enhancing patient outcomes in cancer treatment while fostering innovation and growth in the oncology biologics market. mAbxience S.A. is a a Spain-based biopharmaceutical company focused on the development and commercialization of monoclonal antibody biosimilars.

Regional Insights

North America was the largest region in the global oncology biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the oncology biosimilars market report forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Oncology Biosimilars Market?

The oncology biosimilars market consists of sales of Ogivri, Herzuma, Ontruzant, and Trazimera. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Oncology Biosimilars Market Report 2026?

The oncology biosimilars market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the oncology biosimilars industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Oncology Biosimilars Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2026 $12.83 billion
Revenue Forecast In 2035 $21.28 billion
Growth Rate CAGR of 13.0% from 2026 to 2035
Base Year For Estimation 2025
Actual Estimates/Historical Data 2020-2025
Forecast Period 2026 - 2030 - 2035
Market Representation Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered Drug Type, Cancer Type, Distribution Type
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled Biocon Biologics Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen Inc., F. Hoffmann-La Roche
Customization ScopeRequest for Customization
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Oncology Biosimilars Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Oncology Biosimilars Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Oncology Biosimilars Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Oncology Biosimilars Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Digitalization, Cloud, Big Data & Cybersecurity

4.1.3 Industry 4.0 & Intelligent Manufacturing

4.1.4 Artificial Intelligence & Autonomous Intelligence

4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems

4.2. Major Trends

4.2.1 Rising Adoption Of Rituximab, Trastuzumab, And Bevacizumab Biosimilars

4.2.2 Increasing Use Of Immunomodulators And Hematopoietic Agents In Cancer Therapy

4.2.3 Growth In G-Csf Biosimilars For Neutropenia Management

4.2.4 Expansion Of Hospital And Retail Pharmacy Channels For Oncology Biosimilars

4.2.5 Focus On Cost-Effective And Accessible Cancer Treatment Options

5. Oncology Biosimilars Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Retail Pharmacies

5.3 Online Pharmacies

5.4 Cancer Treatment Centers

5.5 Contract Research Organizations (Cros)

6. Oncology Biosimilars Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Oncology Biosimilars Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Oncology Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Oncology Biosimilars Market Size, Comparisons And Growth Rate Analysis

7.3. Global Oncology Biosimilars Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Oncology Biosimilars Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Oncology Biosimilars Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Oncology Biosimilars Market Segmentation

9.1. Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)

9.2. Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types

9.3. Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

9.4. Global Oncology Biosimilars Market, Sub-Segmentation Of Monoclonal Antibody, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Rituximab Biosimilars, Trastuzumab Biosimilars, Bevacizumab Biosimilars, Pembrolizumab Biosimilars

9.5. Global Oncology Biosimilars Market, Sub-Segmentation Of Immunomodulators, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Thalidomide Biosimilars, Lenalidomide Biosimilars, Pomalidomide Biosimilars

9.6. Global Oncology Biosimilars Market, Sub-Segmentation Of Hematopoietic Agents, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Epoetin Biosimilars, Darbepoetin Biosimilars

9.7. Global Oncology Biosimilars Market, Sub-Segmentation Of Granulocyte Colony-Stimulating Factor (G-CSF), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Filgrastim Biosimilars, Pegfilgrastim Biosimilars

10. Oncology Biosimilars Market Regional And Country Analysis

10.1. Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Oncology Biosimilars Market

11.1. Asia-Pacific Oncology Biosimilars Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Oncology Biosimilars Market

12.1. China Oncology Biosimilars Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Oncology Biosimilars Market

13.1. India Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Oncology Biosimilars Market

14.1. Japan Oncology Biosimilars Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

14.2. Japan Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Oncology Biosimilars Market

15.1. Australia Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Oncology Biosimilars Market

16.1. Indonesia Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Oncology Biosimilars Market

17.1. South Korea Oncology Biosimilars Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

17.2. South Korea Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Oncology Biosimilars Market

18.1. Taiwan Oncology Biosimilars Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

18.2. Taiwan Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Oncology Biosimilars Market

19.1. South East Asia Oncology Biosimilars Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

19.2. South East Asia Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Oncology Biosimilars Market

20.1. Western Europe Oncology Biosimilars Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

20.2. Western Europe Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Oncology Biosimilars Market

21.1. UK Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Oncology Biosimilars Market

22.1. Germany Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Oncology Biosimilars Market

23.1. France Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Oncology Biosimilars Market

24.1. Italy Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Oncology Biosimilars Market

25.1. Spain Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Oncology Biosimilars Market

26.1. Eastern Europe Oncology Biosimilars Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

26.2. Eastern Europe Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Oncology Biosimilars Market

27.1. Russia Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Oncology Biosimilars Market

28.1. North America Oncology Biosimilars Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

28.2. North America Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Oncology Biosimilars Market

29.1. USA Oncology Biosimilars Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

29.2. USA Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Oncology Biosimilars Market

30.1. Canada Oncology Biosimilars Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

30.2. Canada Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Oncology Biosimilars Market

31.1. South America Oncology Biosimilars Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

31.2. South America Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Oncology Biosimilars Market

32.1. Brazil Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Oncology Biosimilars Market

33.1. Middle East Oncology Biosimilars Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

33.2. Middle East Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Oncology Biosimilars Market

34.1. Africa Oncology Biosimilars Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

34.2. Africa Oncology Biosimilars Market, Segmentation By Drug Type, Segmentation By Cancer Type, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Oncology Biosimilars Market Regulatory and Investment Landscape

36. Oncology Biosimilars Market Competitive Landscape And Company Profiles

36.1. Oncology Biosimilars Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Oncology Biosimilars Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Oncology Biosimilars Market Company Profiles

36.3.1. Biocon Biologics Limited Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Celltrion Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Intas Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis

36.3.5. STADA Arzneimittel AG Overview, Products and Services, Strategy and Financial Analysis

37. Oncology Biosimilars Market Other Major And Innovative Companies

Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen Inc., F. Hoffmann-La Roche, Sanofi SA, Mylan, Samsung Bioepis, Biogen International GmbH, Merck & Co. Inc., Coherus Biosciences, Eli Lilly and Company, Novartis AG

38. Global Oncology Biosimilars Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Oncology Biosimilars Market

40. Oncology Biosimilars Market High Potential Countries, Segments and Strategies

40.1 Oncology Biosimilars Market In 2030 - Countries Offering Most New Opportunities

40.2 Oncology Biosimilars Market In 2030 - Segments Offering Most New Opportunities

40.3 Oncology Biosimilars Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Oncology Biosimilars Market, Overview Of Key Products - Product Examples
  • Table 2: Global Oncology Biosimilars Market Attractiveness, Factor-Wise Evaluation
  • Table 3: Global Oncology Biosimilars Market, Supply Chain Analysis
  • Table 4: Global Oncology Biosimilars Market, Major Raw Material Providers
  • Table 5: Global Oncology Biosimilars Market, Major Resource Providers
  • Table 6: Global Oncology Biosimilars Market, Major Manufacturers (Suppliers)
  • Table 7: Global Oncology Biosimilars Market, Major Distributors And Channel Partners
  • Table 8: Global Oncology Biosimilars Market, Key Technologies & Future Trends
  • Table 9: Global Oncology Biosimilars Market, Major Trends
  • Table 10: Global Oncology Biosimilars Market, Major End Users
  • Table 11: Global Oncology Biosimilars Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Table 12: Global Oncology Biosimilars Historic Market Growth, 2020-2025, $ Billion
  • Table 13: Global Oncology Biosimilars Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Table 14: Global Oncology Biosimilars Market - TAM, US$ Billion, 2025
  • Table 15: Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 16: Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 17: Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 18: Global Oncology Biosimilars Market, Sub-Segmentation Of Monoclonal Antibody, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 19: Global Oncology Biosimilars Market, Sub-Segmentation Of Immunomodulators, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 20: Global Oncology Biosimilars Market, Sub-Segmentation Of Hematopoietic Agents, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 21: Global Oncology Biosimilars Market, Sub-Segmentation Of Granulocyte Colony-Stimulating Factor (G-CSF), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 22: Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 23: Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 24: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 25: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 26: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 27: China, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 28: China, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 29: China, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 30: India, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 31: India, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 32: India, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 33: Japan, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 34: Japan, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 35: Japan, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 36: Australia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 37: Australia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 38: Australia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 39: Indonesia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 40: Indonesia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 41: Indonesia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 42: South Korea, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 43: South Korea, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 44: South Korea, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 45: Taiwan, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 46: Taiwan, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 47: Taiwan, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 48: South East Asia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 49: South East Asia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 50: South East Asia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 51: Western Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 52: Western Europe, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 53: Western Europe, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 54: UK, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 55: UK, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 56: UK, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 57: Germany, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 58: Germany, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 59: Germany, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 60: France, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 61: France, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 62: France, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 63: Italy, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 64: Italy, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 65: Italy, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 66: Spain, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 67: Spain, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 68: Spain, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 69: Eastern Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 70: Eastern Europe, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 71: Eastern Europe, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 72: Russia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 73: Russia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 74: Russia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 75: North America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 76: North America, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 77: North America, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 78: USA, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 79: USA, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 80: USA, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 81: Canada, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 82: Canada, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 83: Canada, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 84: South America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 85: South America, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 86: South America, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 87: Brazil, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 88: Brazil, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 89: Brazil, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 90: Middle East, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 91: Middle East, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 92: Middle East, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 93: Africa, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 94: Africa, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 95: Africa, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 96: Global Oncology Biosimilars Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Table 97: Global Oncology Biosimilars Market - Company Scoring Matrix
  • Table 98: Biocon Biologics Limited Financial Performance
  • Table 99: Celltrion Inc. Financial Performance
  • Table 100: Dr. Reddy's Laboratories Ltd. Financial Performance
  • Table 101: Intas Pharmaceuticals Ltd. Financial Performance
  • Table 102: STADA Arzneimittel AG Financial Performance
  • Table 103: Global Oncology Biosimilars Market, Competitive Benchmarking (In USD Billions)
  • Table 104: Global Oncology Biosimilars Market, Competitive Dashboard
  • Table 105: Global Oncology Biosimilars Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Table 106: Global, Oncology Biosimilars Market Size Gain ($ Billion), Segmentation By Drug Type, 2025 – 2030
  • Table 107: Global, Oncology Biosimilars Market Size Gain ($ Billion), Segmentation By Cancer Type, 2025 – 2030
  • Table 108: Global, Oncology Biosimilars Market Size Gain ($ Billion), Segmentation By Distribution Type, 2025 – 2030

List Of Figures

    Figure 1: Global Oncology Biosimilars Market, Overview Of Key Products - Product Examples
  • Figure 2: Global Oncology Biosimilars Market Attractiveness, Factor-Wise Evaluation
  • Figure 3: Global Oncology Biosimilars Market, Supply Chain Analysis
  • Figure 4: Global Oncology Biosimilars Market, Major Raw Material Providers
  • Figure 5: Global Oncology Biosimilars Market, Major Resource Providers
  • Figure 6: Global Oncology Biosimilars Market, Major Manufacturers (Suppliers)
  • Figure 7: Global Oncology Biosimilars Market, Major Distributors And Channel Partners
  • Figure 8: Global Oncology Biosimilars Market, Key Technologies & Future Trends
  • Figure 9: Global Oncology Biosimilars Market, Major Trends
  • Figure 10: Global Oncology Biosimilars Market, Major End Users
  • Figure 11: Global Oncology Biosimilars Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Figure 12: Global Oncology Biosimilars Historic Market Growth, 2020-2025, $ Billion
  • Figure 13: Global Oncology Biosimilars Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Figure 14: Global Oncology Biosimilars Market - TAM, US$ Billion, 2025
  • Figure 15: Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 16: Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 17: Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 18: Global Oncology Biosimilars Market, Sub-Segmentation Of Monoclonal Antibody, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 19: Global Oncology Biosimilars Market, Sub-Segmentation Of Immunomodulators, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 20: Global Oncology Biosimilars Market, Sub-Segmentation Of Hematopoietic Agents, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 21: Global Oncology Biosimilars Market, Sub-Segmentation Of Granulocyte Colony-Stimulating Factor (G-CSF), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 22: Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 23: Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 24: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 25: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 26: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 27: China, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 28: China, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 29: China, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 30: India, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 31: India, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 32: India, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 33: Japan, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 34: Japan, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 35: Japan, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 36: Australia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 37: Australia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 38: Australia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 39: Indonesia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 40: Indonesia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 41: Indonesia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 42: South Korea, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 43: South Korea, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 44: South Korea, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 45: Taiwan, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 46: Taiwan, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 47: Taiwan, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 48: South East Asia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 49: South East Asia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 50: South East Asia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 51: Western Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 52: Western Europe, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 53: Western Europe, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 54: UK, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 55: UK, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 56: UK, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 57: Germany, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 58: Germany, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 59: Germany, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 60: France, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 61: France, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 62: France, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 63: Italy, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 64: Italy, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 65: Italy, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 66: Spain, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 67: Spain, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 68: Spain, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 69: Eastern Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 70: Eastern Europe, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 71: Eastern Europe, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 72: Russia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 73: Russia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 74: Russia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 75: North America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 76: North America, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 77: North America, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 78: USA, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 79: USA, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 80: USA, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 81: Canada, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 82: Canada, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 83: Canada, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 84: South America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 85: South America, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 86: South America, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 87: Brazil, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 88: Brazil, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 89: Brazil, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 90: Middle East, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 91: Middle East, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 92: Middle East, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 93: Africa, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 94: Africa, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 95: Africa, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 96: Global Oncology Biosimilars Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Figure 97: Global Oncology Biosimilars Market - Company Scoring Matrix
  • Figure 98: Biocon Biologics Limited Financial Performance
  • Figure 99: Celltrion Inc. Financial Performance
  • Figure 100: Dr. Reddy's Laboratories Ltd. Financial Performance
  • Figure 101: Intas Pharmaceuticals Ltd. Financial Performance
  • Figure 102: STADA Arzneimittel AG Financial Performance
  • Figure 103: Global Oncology Biosimilars Market, Competitive Benchmarking (In USD Billions)
  • Figure 104: Global Oncology Biosimilars Market, Competitive Dashboard
  • Figure 105: Global Oncology Biosimilars Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Figure 106: Global, Oncology Biosimilars Market Size Gain ($ Billion), Segmentation By Drug Type, 2025 – 2030
  • Figure 107: Global, Oncology Biosimilars Market Size Gain ($ Billion), Segmentation By Cancer Type, 2025 – 2030
  • Figure 108: Global, Oncology Biosimilars Market Size Gain ($ Billion), Segmentation By Distribution Type, 2025 – 2030

Dental Sleep Medicine Growth Trajectory: Key Forecasts and Strategic Insights

Read More About Dental Sleep Medicine Growth Trajectory: Key Forecasts and Strategic Insights

Dipeptide Peptidase 4 Inhibitors Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

Read More About Dipeptide Peptidase 4 Inhibitors Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

Emerging Trends Redefining the Dipeptide Peptidase 4 Inhibitors Market Landscape: Advancements In Epilepsy Treatment Solutions By Leading Pharmaceutical Companies

Read More About Emerging Trends Redefining the Dipeptide Peptidase 4 Inhibitors Market Landscape: Advancements In Epilepsy Treatment Solutions By Leading Pharmaceutical Companies

Top Trends Driving Innovation and Change in the Gastroparesis Drugs Market: Development Of Innovative Gastroparesis Treatment

Read More About Top Trends Driving Innovation and Change in the Gastroparesis Drugs Market: Development Of Innovative Gastroparesis Treatment

Uncover TBRC’s strategic outlook on technological trends, regulatory factors, and market growth in transdermal drug delivery systems.

Read More About Uncover TBRC’s strategic outlook on technological trends, regulatory factors, and market growth in transdermal drug delivery systems.

Explore forecast data, therapeutic advancements, and pipeline progress in TBRC’s Tuberous Sclerosis Drug Market report.

Read More About Explore forecast data, therapeutic advancements, and pipeline progress in TBRC’s Tuberous Sclerosis Drug Market report.

Gain insights into strategic developments and market forecasts for the tissue plasminogen activator market.

Read More About Gain insights into strategic developments and market forecasts for the tissue plasminogen activator market.

Explore the impact of innovative phytocine lines on the herbal medicine market in 2025.

Read More About Explore the impact of innovative phytocine lines on the herbal medicine market in 2025.

Pharmaceuticals Global Market Report 2022 – By Type (Pharmaceutical Drugs, Biologics), By Distribution Channel (Supermarkets/Hypermarkets, Convenience Stores, E-Commerce), By Nature (Organic, Conventional) – Market Size,...

Biosimilars Market Report 2026 - Global Outlook – By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones), By Protein Type (Recombinant Non-glycosylated Proteins, R...

Biosimilar Growth Hormones Market Report 2026 - Global Outlook – By Route Of Administration (Subcutaneous, Intramuscular, Oral ), By Application (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prad...

Biosimilar Monoclonal Antibodies Market Report 2026 - Global Outlook – By Type (Biopharmaceuticals, Other Types), By Compound (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab), By Application (Chro...

Biosimilar Therapeutic Peptides Market Report 2026 - Global Outlook – By Type (Innovative, Generic), By Route Of Administration (Parenteral Route, Transdermal Route, Other Route Of Administrations ), By Application (Canc...

Biosimilar Hormones Market Report 2026 - Global Outlook – By Type (Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types), By Application (Research & Biotechnolo...

Biosimilar Interleukins Market Report 2026 - Global Outlook – By Type (IL-17, IL-23, IL-1, IL-5, IL-6), By Application (Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Othe...

Biosimilar Lymphocyte Modulator Market Report 2026 - Global Outlook – By Drug (Campath-1H, Natalizumab Biosimilar, Efalizumab - A1089-Anti-CD11a Biosimilar, Anti-CD38 Daratumumab Biosimilar, Anti-CS1 Elotuzumab Biosimila...

Frequently Asked Questions

The Oncology Biosimilars Market Report 2026 market was valued at $11.35 billion in 2025, increased to $12.83 billion in 2026, and is projected to reach $21.28 billion by 2030. request a sample here

The expected CAGR for the Oncology Biosimilars Market Report 2026 market during the forecast period 2025–2030 is 13.5%. request a sample here

Major growth driver of the market includes: Patent Expirations Drive New Oncology Biosimilars in the Oncology Biosimilars Market Report 2026 market. For further insights on this market, request a sample here

The oncology biosimilars market covered in this report is segmented –
1) By Drug Type: Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)
2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types
3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments:
1) By Monoclonal Antibody: Rituximab Biosimilars, Trastuzumab Biosimilars, Bevacizumab Biosimilars, Pembrolizumab Biosimilars
2) By Immunomodulators: Thalidomide Biosimilars, Lenalidomide Biosimilars, Pomalidomide Biosimilars
3) By Hematopoietic Agents: Epoetin Biosimilars, Darbepoetin Biosimilars
4) By Granulocyte Colony-Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars request a sample here

Major trend in this market includes: Increasing Focus On Investments To Support The Battle Of Cancer For further insights on this market, request a sample here.

Major companies operating in the Oncology Biosimilars Market Report 2026 market are Major companies operating in the oncology biosimilars market are Biocon Biologics Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., ST request a sample here.

North America was the largest region in the global oncology biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the oncology biosimilars market report forecast period. The regions covered in the oncology biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us